The project, which could cost up to $500 billion, was described by Trump as the "largest AI infrastructure project in history ...

As of January 31 at 3:58:55 PM EST. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.

Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

The mRNA-1273.815 vaccine provided significant protection against COVID-19-related hospitalizations and medically attended COVID-19 among US adults.

Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $60.0 for Moderna over the recent three months. Looking at the volume ...

Chairman Larry Ellison highlighted the AI's potential in the development of mRNA-based cancer vaccines. Read more here.

But scientists at Moderna are in the late stages of testing what could be the first such shot, using mRNA technology against the virus. Here’s what to know about norovirus and where things stand ...

President Joe Biden's outgoing administration on Thursday announced $211 million in new funding to develop mRNA vaccines against emerging biothreats and said it was accelerating bird flu testing, as ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business ...